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Randomized comparison of percutaneous Viabahn
stent grafts vs prosthetic femoral-popliteal bypass
in the treatment of superficial femoral arterial
occlusive disease
John Kedora, MD, Stephen Hohmann, MD, Wilson Garrett, MD, Cary Munschaur, BS,
Brian Theune, MD, and Dennis Gable, MD, Dallas, Tex
Objective: This randomized prospective study was designed to compare the effectiveness of treating superficial femoral
artery occlusive disease percutaneously with expanded polytetrafluoroethylene (ePTFE)/nitinol self-expanding stent
grafts vs surgical femoral-to-above knee (AK) popliteal artery bypass with synthetic graft material.
Methods: From March 2004 to May 2005, 100 limbs in 86 patients with femoral-popliteal arterial occlusive disease were
identified. Patients had symptoms ranging from claudication to rest pain, with or without tissue loss, and were
prospectively randomized for treatment into one of two groups. The limbs were treated percutaneously with angioplasty
and one or more self-expanding stent grafts (n  50) or surgically with femoral-to-AK popliteal artery bypass using
synthetic Dacron or ePTFE grafts (n  50). The mean  SD total length of artery stented was 25.6  15 cm. Follow-up
evaluation with ankle-brachial indices and color flow duplex sonography imaging were performed at 3, 6, 9, and 12
months after treatment.
Results: Patients were monitored for a median of 18 months. No statistical difference was found in the primary patency
(P .895) or secondary patency (P .861) between the two treatment groups. Primary patency at 3, 6, 9, and 12months
of follow-up was 84%, 82%, 75.6%, and 73.5% for the stent graft group and 90%, 81.8%, 79.7%, and 74.2% for the
femoral-popliteal surgical group. Thirteen patients in the stent graft group had 14 reinterventions, and 12 reinterven-
tions occurred in the surgical group. This resulted in secondary patency rates of 83.9% for the stent graft group and 83.7%
for the surgical group at the 12-month follow-up.
Conclusions: Management of femoral-popliteal arterial occlusive disease using percutaneous treatment with a stent graft
is comparable with surgical revascularization with conventional femoral-to-AK popliteal artery bypass using synthetic
material up to 12 months. Longer-term follow-up would be helpful in determining ongoing efficacy. (J Vasc Surg 2007;
45:10-16.)Endovascular therapy has dramatically altered the treat-
ment of peripheral arterial disease. Lesions previously
thought amenable only to open surgical bypass can now be
successfully managed percutaneously. In an international
trial study group, Lammer et al1 deployed the Hemobahn
endoprosthesis (W. L. Gore & Associates, Flagstaff, Ariz)
in 80 limbs with occlusive femoral-popliteal lesions. A
primary patency of 90% at 6 months and 79% at 12 months
was achieved. Subsequent to this report, the graft delivery
system was modified (although the graft itself remained
without change), and it was renamed the Viabahn endo-
prosthesis.
Ultimately, percutaneous endovascular treatment of
superficial femoral arterial occlusive disease will not be
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10fully embraced until direct comparisons are made with
open surgical bypass. Although most consider vein by-
pass to be the gold standard in surgical treatment of
severe atherosclerotic disease, synthetic grafting is often
used in current practice for femoral–popliteal above knee
(AK) bypass. The purpose of our study was to compare
the efficacy of the stent graft vs open surgical femo-
ral–AK popliteal bypass in the treatment of superficial
arterial occlusive disease.
MATERIALS AND METHODS
Study design. The study was a prospective, random-
ized trial conducted at a single private institution between
March 2004 andMay 2005. The study was approved by the
US Food and Drug Administration (FDA) with an investi-
gational device exemption (IDE) and was approved and
monitored by the hospital Institutional Review Board.
During the study period, patients with symptoms of
lifestyle-altering claudication or rest pain with or without
tissue loss were evaluated for treatment. A clinical exami-
nation and non-invasive studies, including the ankle-
brachial index (ABI) and color-flow duplex ultrasonogra-
phy, were used to confirm infrainguinal disease. Patients
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(DSA) or computed tomography angiography (CTA) to
evaluate the location and extent of atherosclerotic disease in
the infrainguinal segment.
To be included in the study, patients had to have
atherosclerotic stenotic or occlusive lesions of the superfi-
cial femoral artery, with no significant aortoiliac disease. In
addition, the infrapopliteal segment had to be patent and at
least one single vessel run-off to the ankle had to be present.
Patients had to be acceptable surgical candidates in the
event they were randomized to the surgical arm.
Enrolled patients were prospectively randomized by
limb into two treatment groups: percutaneous endovascular
treatment with the stent graft, or open surgical femoral–AK
popliteal artery bypass with synthetic graft.
Study population. Between March 2004 and May
2005, 100 limbs in 86 patients met the inclusion criteria.
Forty patients (50 limbs) were randomized to treatment
with the stent graft, and 46 patients (50 limbs) were
randomized to treatment with femoral–AK popliteal artery
bypass. In four patients undergoing treatment for bilateral
disease, one limbwas randomized into the stent graft group
and one limb was randomized into the surgical bypass
group. The demographic data and associated comorbidities
are summarized in Table I. Although there was a significant
difference in patient age between the two treatment
groups, no significant difference was found in the patient
comorbidities.
Stent graft design. The stent graft that was used for
endovascular treatment was made from a self-expanding
helical nitinol stent and a tube of ultra-thin expanded
polytetrafluoroethylene (ePTFE). Although the graft was
not FDA-approved for use in the superficial femoral artery
(SFA) at the outset of this study, current FDA-approved
graft sizes for use in the SFA are 6 to 8 mm in diameter and
2.5 to 15 cm in length.
Endovascular technique. All procedures were per-
formed under sterile conditions in an endovascular suite
with a fixed imaging unit or in an operating room suite with




Patients (n) 40 46







Smoking history 22 27 .8280‡
Diabetes mellitus 14 20 .5090‡
CAD 13 22 .1886‡
Hypertension 30 42 .0763‡
Hyperlipidemia 23 21 .2862‡
COPD 2 8 .0973‡
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary dis-
ease.
*Four patients randomized a limb to both treatment groups.
†Two-tailed t-test with pooled variances.
‡Two-tailed Fisher’s exact test.a C-arm (General Electric OEC 9800, GE Healthcare,Waukesha, Wisc). Percutaneous vascular access was ob-
tained by standard Seldinger technique2 from either the
ipsilateral femoral artery in an antegrade manner or from
the contralateral femoral artery. Once access was achieved,
a 45-cm-long 8F or 9F sheath was inserted, depending on
the diameter of stent graft to be deployed. Systemic heparin
(100 U/kg) was then administered to fully anticoagulate
the patient.
Standard guidewire techniques were used to cross the
atherosclerotic lesion. Occlusions were crossed using a
subintimal dissection technique with re-entry into the true
lumen. Predilation of the lesion then was performed with a
4 or 5 mm angioplasty balloon. The length of the balloon
was selected to dilate only the lesion to be treated and to
avoid dilatation of any nonstenotic vessel.
The stent graft was deployed to cover the entire dis-
eased arterial segment. Grafts with diameters of 5 to 7 mm
were used, depending on the diameter of the native artery;
most were 5 mm. If possible, the graft was deployed so that
it landed with the stent margins nomore than 1 cm into the
segment of normal artery superiorly and inferiorly. Care
was taken not to cover large collateral vessels, if feasible,
while ensuring coverage of the diseased segment of artery.
When multiple stent grafts were used for longer lesions, the
devices were overlapped by at least 1 cm.
After deployment, the stent grafts were dilated and
modeled with a 5-mm, 6-mm, or 7-mm balloon to corre-
spond with the size of the stent used, and completion
angiography was performed. Specific attention was given
not to dilate outside the stent graft. Lesion length and
length of stented artery segments were measured with
calibrated in-plane markers at the time of the initial proce-
dure.
After treatment, patients were started on aspirin (81 to
325 mg/d) and clopidogrel (75 mg/d) therapy for a
minimum of 3 months. Patients who were receiving warfa-
rin therapy before treatment for other associated conditions
were continued on the drug in addition to aspirin at 81mg/d.
Clopidogrel was not used in these patients.
Open surgical technique. Femoral–AK popliteal ar-
tery bypass was accomplished in the usual surgical fashion.
After standard surgical exposure of the vessels, each patient
was systemically anticoagulated with heparin (100 U/kg)
before graft insertion. The choice of conduit was left to the
discretion of the operating surgeon and was either ePTFE
or Dacron. Graft diameters were 6 to 8 mm; most were
7 mm. Postoperatively, patients were placed on an anti-
platelet regimen similar to that described for the stent graft
patients.
Postoperative assessment and follow-up examina-
tion. After discharge, follow-up at 3, 6, 9, and 12
months included clinical exam, color flow Doppler ultra-
sound imaging, and determination of the ABI. Color
flow Doppler ultrasound imaging was performed at a
laboratory approved by the Intersocietal Commission for
the Accreditation of Vascular Laboratories and was used
to assess patency of grafts and to detect recurrent arterial
or graft stenosis. Primary and secondary patency rates
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scribed by Rutherford.3 Graft failure was defined as stent
graft or bypass graft thrombosis, restenosis of 50% of
the treated arterial segment immediately above or below
the stent graft or bypass graft (anastomotic or stent
landing zone sites), intrastent or intragraft restenosis
50%, or a decrease in the ABI of 0.15.
Statistical analysis. The life-table method was used
to calculate primary and secondary patency rates vs time
of follow-up. The log-rank test was used to determine
the statistical difference between patency rates between
the two treatment groups. The Fisher exact test (gener-
alized version for tables beyond 2  2) was used to
evaluate differences in patient demographics, grades of
chronic limb ischemia, and TransAtlantic Inter-Society
Consensus (TASC) classification. P  .05 was consid-
ered statistically significant. Mean data are presented
with  SD or ranges.
RESULTS
Between March 2004 and May 2005, 50 limbs in 40
patients were treated percutaneously with the stent graft,
and 50 limbs in 46 patients were treated surgically with
femoral–AK popliteal artery bypass.
Pretreatment clinical categories of chronic limb isch-
emia using Rutherford’s classification3 for the treated limbs
are shown in Table II. No significant difference in pretreat-
ment clinical grades between the two treatment groups was
noted.
By following the TASC grading system4 for femoro-
popliteal lesions, each limb in both treatment groups was
Table III. Lesion TransAtlantic Inter-Society Consensus
(TASC) classification per limb





Generalized Fisher’s exact test, P  .4739.















Generalized Fisher’s exact test, P  .3676.assigned a TASC classification as summarized in Table III.The TASC classifications between the two treatment
groups were not significantly different.
Stent graft placement was technically successful in
100% of the treated limbs in the stent graft treatment
group. A total of 114 devices were implanted in the 50
limbs, with a mean of 2.3 stent grafts placed per limb. The
mean diameter of the stent grafts was 5.7 mm (range, 5 to
7 mm). The mean total length of artery covered with the
stent graft was 25.6  15 cm.
After treatment, 37 (93%) of 40 patients in the stent
graft group took clopidogrel and aspirin for a minimum of
3 months. One patient claimed an allergy to clopidogrel,
and two others refused to take it. These three patients did
take aspirin, however.
Femoral–AK popliteal artery bypass was successfully
performed in 100% of the treated limbs in the surgical
treatment group. Dacron grafts were used in 32 limbs
(64%), and ePTFE was used in 18 limbs (36%). The mean
diameter of the synthetic bypass grafts was 7.4 mm (range,
7 to 8 mm).
In the surgical bypass group, 24 (52%) of 46 patients
were on a clopidogrel and aspirin regimen post-treatment.
Seventeen patients were taking aspirin only as recom-
mended by the treating surgeon. The remaining five pa-
tients were taking warfarin preoperatively and were contin-
ued only on this regimen postoperatively.
Immediate procedure-related and early postopera-
tive, nonthrombotic complications were observed in
four (8%) of 50 limbs (40 patients) treated with the stent
graft. In one patient, a dissection was created in the SFA
during passage of a guidewire. The stent graft was used
to exclude the dissection along with the atherosclerotic
lesion. Another patient experienced transient mild leg
edema in the treated limb. Deep venous thrombosis was
ruled out, and the edema resolved. One patient reported
severe thigh pain in the treated limb that required read-
mission to the hospital for pain management. The pain
resolved 24 hours without any identifiable pathology.
One final patient had a small groin hematoma that
resolved without intervention.
In the surgical bypass group, early postoperative com-
plications were observed in three (6%) of 50 limbs (46
patients). These three patients developed a groin lympho-
cele, a groin seroma, and a small superficial groin wound
dehiscence, respectively. The patient with a groin lympho-
cele was returned to the operating room for washout and
reclosure of the wound. The other two patients were man-
aged nonoperatively.
An improvement in grade of the Rutherford classifica-
tion occurred in all limbs (100%) in the stent graft treat-
ment group and in 46 limbs (92%) in the surgical bypass
group. The overall mean improvement was 2.4 clinical
grades in both groups.
Median follow-up duration was 18 months for both
treatment groups. Follow-up was available for 31 (78%)
of 40 patients in the stent graft group. Four patients died
during the study period from conditions unrelated to
infrainguinal disease, and all but one of these patients
JOURNAL OF VASCULAR SURGERY
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follow-up.
During this period, 13 of the stent grafts failed second-
ary to thrombosis. An early graft thrombosis occurred in
the recovery room the same day of the procedure in one
patient. One stent graft thrombosis occurred within the
first month after stent graft implantation. The other 11
stent graft thromboses were detected after a mean period of
5.4  3 months after stent graft placement.
Of the 13 grafts that thrombosed, five (38%) were
successfully declotted with mechanical balloon thrombec-
tomy and one was successfully recanalized with intra-arterial
tissue plasminogen activator–mediated lysis. In six (46%),
attempts at thrombectomy or lysis were unsuccessful, and
these patients eventually underwent open surgical bypass
(five to the AK popliteal artery). Finally, one of the patients
with a thrombosed stent graft was found to have heparin-
induced thrombocytopenia and amputation eventually was
performed owing to progressive tissue loss. This patient
had tissue loss preoperatively.
In two of the patients who underwent thrombectomy
of their clotted stent grafts, an underlying stenosis was
detected after post-thrombectomy angiography. One pa-
tient had a high-grade stenosis just distal to the stent graft.
The other patient had a proximal stenosis. In both cases,
the stenotic area was treated with angioplasty and stent
graft placement.
In one patient (two limbs), both lower extremities
thrombosed simultaneously. This patient was found to
have bilateral lower extremity embolization after new onset
atrial fibrillation. Thirty days before occlusion, a routine
follow-up arterial duplex demonstrated no stenosis within
either limb and the patient had palpable bilateral pedal
pulses. One limb was eventually opened with thrombec-
tomy, but the other limb required femoral–below-knee
bypass for limb salvage.
Another patient in the stent graft group with a patent
graft was found to have a short segment proximal arterial
stenosis detected at follow-up color flow duplex sonogra-
phy imaging, which was confirmed at angiography to be
approximately 30% to 40%. This segment was treated with
angioplasty alone. Overall, 14 interventions had to be
performed in the stent graft treatment group during 12
months.
None of the three patients in the stent graft group that
were not taking clopidogrel after treatment had a throm-
bosed stent graft. Of the 13 thrombosed stent grafts, 11
(84%) were TASC C lesions. Of the other two thrombosed
grafts, one (8%) was a TASC A lesion and one (8%) was a
TASC D lesion.
Follow-up was available for 37 (80%) of 46 patients in
the surgical bypass group. Four patients died owing to
conditions unrelated to their infrainguinal disease. Five
patients were lost to follow-up.
During this period, 10 incidences of synthetic graft
thrombosis occurred, of which seven (70%) were TASC
C lesions and three (30%) were TASC D lesions; none
were TASC A or B lesions. One occurred within the firstmonth after implantation. The other nine were detected
a mean of 6.9  4 months after graft placement. Four of
the 10 thrombosed synthetic grafts were successfully
declotted with mechanical balloon thrombectomy.
Three patients underwent below knee popliteal artery
bypass with great saphenous vein conduit after throm-
bectomy failed.
In three separate instances, ischemia from clotted grafts
eventually led to below knee amputation. In two additional
cases, progressive tissue loss despite patent grafts led to two
additional amputations. All instances of limb amputation
occurred in patients that had tissue loss preoperatively.
One patient in the surgical group with a patent graft
was found on follow-up duplex ultrasound to have a distal
native arterial stenosis. This was confirmed at angiography,
and the stenosis was treated with balloon angioplasty and
stent placement. As already mentioned, one patient with a
groin lymphocele had an operative intervention. Overall,
12 interventions had to be performed in the surgical bypass
group during 12 months.
Cumulative primary and secondary patency rates
were calculated with use of the life-table method. At
follow-up at 3, 6, 9 and 12 months, the respective
primary patency rates were 84.0%, 82.0%, 75.6%, and
73.5%, for the stent graft group and 90.0%, 81.8%,
79.7%, and 74.2% for the surgical bypass group (Table
IV). Secondary patency at the 12-month follow-up was
83.7% for the stent graft group and 83.9% for the surgical
bypass group (Table V). There was no significant differ-
ence in primary patency (P .895) or secondary patency
(P  .861) between the two treatment groups. Limb
salvage at the 12-month follow-up was not significantly
different at 98.0% for the stent graft patients and 89.6%
for surgical bypass patients (P  .094) (Table VI).
Baseline ABIs were were 0.57  0.19 for the stent graft
group and 0.46  0.22 for the surgical bypass group. At
12 months, the mean improvement in ABI was 0.23 for
the stent graft treatment group and 0.37 for the surgical
bypass group (P  .113).
Length of hospital stay was analyzed for both groups.
The mean hospital stay was 0.9  0.8 days for the stent
graft group was and 3.1  1.8 days for the surgical group.
This difference proved to be significant (t test, P  .001).
DISCUSSION
Initial attempts to treat SFA atherosclerotic disease
percutaneously were made with transluminal angioplasty
(PTA).5 Although effective in short-segment stenosis, PTA
has been disappointing as a primary treatment for longer
SFA stenosis.6 Further investigation led to the use of an-
gioplasty, followed by stent placement. The results of these
studies were equivocal to PTA patency,7 most likely due to
neointimal hyperplasia.
The patency of percutaneously placed stent grafts for
SFA disease was published by Lammer et al in 2000.1 This
multicenter study demonstrated 1-year primary and sec-
ondary patency rates of 79% and 93% in 80 limbs. Bauer-
meister et al8 treated 35 patients and achieved primary and
ons th
ons th
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In 2003, Jahnke et al9 reported primary assisted patency
rates at 12 and 24 months of 82.4% and 80.3%, and
secondary patency was 88.3% and 83.2%.
Our study is the first, to our knowledge, to prospec-
tively randomize patients to percutaneous and surgical arms
in treatment of disease in the SFA and then directly com-
pare the outcomes. The prior 11 studies of stent grafts have
relied on previously published reports of AK bypass patency
and historical data for comparison. Historical controls are
useful, but prospective, randomized trials allow direct com-
parison with the most current therapy.
Our technical success rate of 100%mirrors that of many
other published trials. Complications were seen in 8% of the
Table IV. Primary patency in femoral-popliteal bypass gro
Time post-treatment
(months)





Fem-pop bypass 50 2 (2)
Stent graft 50 2 (2)
3 months (day 31-136)
Fen-pop bypass 48 3 (5)
Stent graft 48 6 (8)
6 months (day 137-227)
Fem-pop bypass 44 4 (9)
Stent graft 41 1 (9)
9 months (day 228-319)
Fem-pop bypass 38 1 (10
Stent graft 39 3 (12
12 months (day 320-456)
Fem-pop bypass 29 2 (12
Stent graft 35 1 (13
CI, Confidence interval.
Log-rank P  .895.
*Number in parenthesis represents cumulative events or censored observati
Table V. Secondary patency in femoropopliteal bypass gro
Time post-treatment
(months)





Fem-pop bypass 50 2 (2)
Stent graft 50 0 (0)
3 months (day 31-136)
Fem-pop bypass 48 2 (4)
Stent graft 50 6 (6)
6 months (day 137-227)
Fem-pop bypass 45 3 (7)
Stent graft 43 1 (7)
9 months (day 228-319)
Fem-pop bypass 40 1 (8)
Stent graft 41 1 (8)
12 months (day 320-456)
Fem-pop bypass 31 0 (8)
Stent graft 39 0 (8)
CI, Confidence interval.
Log-rank P value  .861.
*Number in parenthesis represents cumulative events or censored observatipatient limbs in the percutaneously treated group. Onepatient had to be readmitted to the hospital for severe thigh
pain. Saxon et al10 noted the phenomenon of thigh pain
after stent graft placement. The pain is thought to be
secondary to overdilation of the SFA andmay be avoided by
not oversizing more than 10% of the native diameter.10
Minor complications occurred in two other patients, and
the symptoms of both patients resolved with observation
alone.
Arterial occlusions in the stent graft group were seen
within all TASC classifications. Interestingly, two of these
cases showed there were underlying lesions at the proximal
and distal end of the stent graft that became evident after
removal of the thrombus. They were successfully treated by
angioplasty and stenting. Deutschman et al11 described a




loss of patency 95% CI
0 (0) 0.960 (0.849, 0.990)
0 (0) 0.960 (0.849, 0.990)
1 (1) 0.900 (0.776, 0.957)
1 (1) 0.840 (0.705, 0.917)
2 (3) 0.818 (0.680, 0.901)
1 (2) 0.820 (0.682, 0.902)
8 (11) 0.797 (0.655, 0.885)
1 (3) 0.756 (0.611, 0.854)
8 (19) 0.742 (0.587, 0.846)
7 (10) 0.735 (0.587, 0.837)
rough end of interval.




loss of patency 95% CI
0 (0) 0.960 (0.849, 0.990)
0 (0) 1.000 (1.000, 1.000)
1 (1) 0.920 (0.801, 0.969)
1 (1) 0.880 (0.752, 0.944)
2 (3) 0.859 (0.726, 0.930)
1 (2) 0.860 (0.728, 0.930)
8 (11) 0.837 (0.701, 0.915)
1 (3) 0.839 (0.703, 0.916)
11 (22) 0.837 (0.701, 0.915)
9 (12) 0.839 (0.703, 0.916)








l*similar phenomenon in their series of 17 patients. The
ons th
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of the graft may be due to overdilation with angioplasty and
failure to cover the treatment area sufficiently with the
covered stent.8
Most of the 13 thrombosed stent grafts (84%) were
TASC C lesions. This finding is not surprising and supports
the finding of others that the higher the TASC classification
the lower the patency. Only one of our TASC D lesions
treated thrombosed, but with only five in the group, defin-
itive conclusions cannot reliably be drawn.
All patients treated by endovascular means required
only outpatient care and in most instances were discharged
on the same day, offering various cost savings in their care
and earlier return to normal activities. This is supported by
our length-of-stay analysis that shows a decrease of required
hospital stay of nearly two thirds. The actual cost analysis
was not performed in the current study, but follow-up
analysis is planned. All but one of the patients in the
endovascular group returned to work and normal daily
activities 48 hours, and most were able to return 24
hours.
CONCLUSION
The choice of open surgical bypass vs percutaneously
placed covered stents in the SFA has yet to be fully delin-
eated. Nevertheless, our study shows no significant differ-
ence in synthetic bypass material placed in an open vs an
endovascular fashion. We believe the results demonstrated
in this study represent a significant step in defining endo-
vascular treatment of disease in the SFA. The stent graft
appears to be a viable option for primary SFA revasculariza-
tion, particularly when vein is not available or if the patient
is a poor candidate for conventional bypass. Correct graft
sizing, avoiding overdilation, and not performing angio-
plasty beyond the area of planned stent coverage seem to be
Table VI. Limb salvage in femoropopliteal bypass group a
Time post-treatment
(months)






Fem-pop bypass 50 2 (2)
Stent graft 50 0 (0)
3 months (day 31-136)
Fem-pop bypass 48 1 (3)
Stent graft 50 1 (1)
6 months (day 137-227)
Fem-pop bypass 45 1 (4)
Stent graft 45 0 (1)
9 months (day 228-319)
Fem-pop bypass 40 1 (5)
Stent graft 44 0 (1)
12 months (day 320-456)
Fem-pop bypass 31 0 (5)
Stent graft 42 0 (1)
CI, Confidence interval.
Log-rank P  .094.
*Number in parenthesis represents cumulative events or censored observaticritically important technical facets of successful placement.We plan to continue to follow our cohort to assess longer-
term outcomes.
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Dr Jon Matsumura (Chicago, Ill). Thirty-eight percent of
the patients in the fem-pop group had Rutherford class 4 to 6 vs
18% in the endo group. Did you look at results stratified by CLI or
do you have a multivariate analysis? Patency results may be influ-
enced by the fem-pop group being enriched with patients with
more severe ischemia.
If you did PTA and it looked beautiful, why did you still place
a stent-graft? Did you consider having an arm with PTA and
selective application of the device?
Dr John C. Kedora.We did not consider doing simply a PTA
arm. We went into this study design with the thought that we
would primarily treat patients with the stent graft, regardless of
whether or not their PTA result was adequate. Our experience has
shown this to give better long-term patency. As far as dividing into
a subset of chronic limb ischemia categories, we did not stratify the
data by that method.
Dr Enrico Ascher (Brooklyn, NY). Did you balloon angio-
plasty the lesion before placing the stent or did you place the stent
graft and then balloon it?
Dr Kedora. All lesions were predilated by angioplasty and
then the stent graft was placed. The stent graft was then modeled
with angioplasty post deployment as well.
Dr Ascher. And how many of these were above the knee and
how many were below the knee?
Dr Kedora. All these were placed above the knee.
Dr Takao Ohki (Bronx, NY). I wasn’t quite sure about your
inclusion criteria. But if I may recall, you said that the patient wasbe appropriate based on an attending’s opinion. After all, you had
a number of TASC Type A lesions, as well as B, C and D.
In the TASC document it does say clearly that TASC A is
better treated with interventional treatment, whereas TASC D is
best treated with bypass. The real question is what to do with
TASC B and C. You should have randomized these patients, then
it would have been a much more valuable study.
Dr Kedora. I think you are right that the evidence for TASC
A lesions is that they are definitely better treated with endovascular
means. I also believe, at least in our study, we wanted to do a true
randomized, prospective study. All patients were well informed of
the chance that if they had a less significant lesion that there was the
chance that they would undergo a surgical bypass and, fortunately,
we had patients that agreed to both.
Dr Kenneth Ouriel (Cleveland, Ohio). Sometimes when you
do a study, you become an expert in a technique and you employ
that technique in patients outside of the scope of the study. And so
I have a somewhat politically charged question for you. What do
you think about using these devices for popliteal aneurysms with
the distal portion of the stent graft below the level of the knee
joint?
Dr Kedora. Evaluation for treatment of popliteal aneurysms
with this graft have yet to be done. In most cases, in our treatment
group, there was disease in the proximal portion of the popliteal
artery, and we were comfortable with placing the stent graft, at
least in the proximal portion.
DrOuriel.Did you use these at all in patients that needed the
distal to be below the level of the knee joint?Dr Kedora. No, sir, we did not.
